EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
-1.53%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.26B
AUM Growth
-$105M
(-7.7%)
Cap. Flow
-$59.3M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
60.92%
Holding
343
New
11
Increased
61
Reduced
233
Closed
34
Top Buys
| 1 |
Pinduoduo
PDD
|
$52.2M |
| 2 |
KE Holdings
BEKE
|
$28.2M |
| 3 |
TSMC
TSM
|
$11.8M |
| 4 |
Kanzhun
BZ
|
$5.71M |
| 5 |
iQIYI
IQ
|
$4.15M |
Top Sells
| 1 |
Tencent Music
TME
|
$38.3M |
| 2 |
Trip.com Group
TCOM
|
$19.3M |
| 3 |
Marvell Technology
MRVL
|
$14.8M |
| 4 |
JOYY
JOYY Inc. American Depositary Shares
JOYY
|
$7.98M |
| 5 |
Microsoft
MSFT
|
$6.65M |
Sector Composition
| 1 | Consumer Discretionary | 37.28% |
| 2 | Technology | 32.43% |
| 3 | Communication Services | 9.6% |
| 4 | Healthcare | 8.37% |
| 5 | Real Estate | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Twist Bioscience
TWST
$1.55B
| $455K | 0.04% |
22,246
-2,228
| -9% | -$45.6K |
|
127
Apellis Pharmaceuticals
APLS
$3.55B
| $452K | 0.04% |
4,963
-1,244
| -20% | -$113K |
|
128
Arrowhead Research
ARWR
$4.02B
| $451K | 0.04% |
12,646
-2,033
| -14% | -$72.5K |
|
129
Ionis Pharmaceuticals
IONS
$9.76B
| $451K | 0.04% |
10,988
-384
| -3% | -$15.8K |
|
130
Neurocrine Biosciences
NBIX
$14.3B
| $451K | 0.04% |
4,783
+752
| +19% | +$70.9K |
|
131
Cintas
CTAS
$82.4B
| $450K | 0.04% |
3,620
-648
| -15% | -$80.6K |
|
132
Alkermes
ALKS
$4.94B
| $449K | 0.04% |
14,348
-165
| -1% | -$5.16K |
|
133
Natera
NTRA
$23.1B
| $449K | 0.04% |
9,232
+2,097
| +29% | +$102K |
|
134
Alnylam Pharmaceuticals
ALNY
$59.2B
| $445K | 0.04% |
2,341
+226
| +11% | +$43K |
|
135
Exelixis
EXEL
$10.2B
| $445K | 0.04% |
23,263
+110
| +0.5% | +$2.1K |
|
136
Mercado Libre
MELI
$123B
| $444K | 0.04% |
375
-73
| -16% | -$86.4K |
|
137
Novavax
NVAX
$1.28B
| $444K | 0.04% |
59,792
+561
| +0.9% | +$4.17K |
|
138
Beam Therapeutics
BEAM
$2.11B
| $443K | 0.04% |
13,867
+1,851
| +15% | +$59.1K |
|
139
Vaxcyte
PCVX
$4.29B
| $441K | 0.03% |
8,834
-1,378
| -13% | -$68.8K |
|
140
Prothena Corp
PRTA
$460M
| $439K | 0.03% |
6,427
-1,622
| -20% | -$111K |
|
141
Amicus Therapeutics
FOLD
$2.46B
| $438K | 0.03% |
34,867
+1,109
| +3% | +$13.9K |
|
142
GE HealthCare
GEHC
$34.6B
| $436K | 0.03% |
+5,361
| New | +$436K |
|
143
Pfizer
PFE
$141B
| $434K | 0.03% |
11,829
-1,075
| -8% | -$39.4K |
|
144
Acadia Pharmaceuticals
ACAD
$4.26B
| $433K | 0.03% |
18,068
-799
| -4% | -$19.1K |
|
145
TE Connectivity
TEL
$61.7B
| $432K | 0.03% |
3,079
-337
| -10% | -$47.3K |
|
146
United Therapeutics
UTHR
$18.1B
| $432K | 0.03% |
1,955
+266
| +16% | +$58.8K |
|
147
Thermo Fisher Scientific
TMO
$186B
| $431K | 0.03% |
826
-83
| -9% | -$43.3K |
|
148
Las Vegas Sands
LVS
$36.9B
| $430K | 0.03% |
7,406
-52
| -0.7% | -$3.02K |
|
|
KDNY
149
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $430K | 0.03% |
11,196
+907
| +9% | +$34.8K |
|
|
KRTX
150
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $426K | 0.03% |
1,963
-194
| -9% | -$42.1K |
|